44 research outputs found
Left atrial diverticulum - An unexpected finding in routine transesophageal echocardiography
We report a 55-year-old male patient with lone paroxysmal atrial fibrillation who underwent routine transesophageal echocardiography (TOE) at our institution. In a mid-esophageal 125 degrees three-chamber angulation, a distinct thinning of the left atrial (LA) wall was observed, forming a 7 x 4 mm canal with only a small membrane separating the LA from the pericardial space. Cardiac magnetic resonance imaging diagnosed a small LA diverticulum. To the best of our knowledge, this is the first manuscript describing detection of a small LA diverticulum via TOE
Cardiovalve in mitral valve positionâAdditional solution for valve replacement
We report on a 72 years old male patient with recurrent heart failure hospitalizations caused by severe mitral regurgitation due to severe restriction of the posterior mitral leaflet treated with the transfemoral mitral valve replacement (TMVR) system Cardiovalve. Immediate interventional success was obtained resulting in a quick mobilization and discharge
Left atrial strain predicts exercise capacity in heart failure independently of left ventricular ejection fraction
Aims: We hypothesized that left atrial (LA) remodelling and function are associated with poor exercise capacity as prognostic marker in chronic heart failure (CHF) across a broad range of left ventricular ejection fraction (LVEF).
Methods and results: One hundred seventy-one patients with CHF were analysed [age 65 +/- 11 years, 136 males (80%); 86 heart failure with reduced ejection fraction (HFrEF), 27 heart failure with mid-range ejection fraction (HFmrEF), 58 heart failure with preserved ejection fraction (HFpEF)]. All patients underwent echocardiography and maximal cardiopulmonary exercise testing and were classified according to a prognostic cut-off of peak VO2 (pVO(2); 14 mL/kg/min). Seventy-seven (45%) patients reached pVO(2) = 14 mL/kg/min. Between the two groups, there was a considerable difference in both left atrial volume (LAVi, 53 +/- 24 vs. 44 +/- 18 mL/m(2), P = 0.005) and function (LA reservoir strain 12 +/- 5 vs. 20 +/- 10%, P < 0.0001). Receiver-operating characteristic curves identified LA reservoir strain (area under the curve: 0.73 [0.65-0.80], P < 0.0001) as strong predictor for impaired pVO(2) among all echocardiographic variables; LA reservoir strain < 23% had 37% specificity but a very high sensitivity (96%) in identifying a severely reduced pVO(2). In logistic regression analysis, LA reservoir strain < 23% was associated with a highly increased risk of pVO(2) < 14 mL/kg/min (odds ratio 16.0 [4.7-54.6]; P < 0.0001). The multivariate analysis showed that a reduced LA reservoir strain was associated with pVO(2) < 14 mL/kg/min after adjustment for age, body mass index (BMI), and clinical variables, that is, New York Heart Association class, atrial fibrillation, haemoglobin, and creatinine (b 0.22 [95% confidence interval, CI, 0.12-0.31]; P < 0.0001), and after adjustment for echocardiographic variables, that is, LVEF or left ventricular global longitudinal strain (LVGLS) and tricuspid annular plane systolic excursion (TAPSE) (b 0.16 [95% CI 0.08-0.24]; P < 0.0001). Patients with HFrEF, HFmrEF, and HFpEF were separately analysed. Among LA reservoir strain, LAVi, LVEF, LVGLS, and TAPSE, LA reservoir strain was the only one significantly associated with pVO(2) in all subgroups (after adjustment for sex and BMI, P = 0.003, 0.04, and 0.01, respectively).
Conclusions: In patients with CHF, an impaired LA reservoir function is independently associated with a severely reduced pVO(2). LA dysfunction represents a marker of poor prognosis across LVEF borders in the CHF population
The effect of sacubitril/valsartan on left ventricular myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial)
Background:
Global longitudinal strain (GLS) and global circumferential strain (GCS) have been shown to be impaired in heart failure with preserved ejection fraction. We sought to assess whether treating patients with heart failure with preserved ejection fraction with sacubitril/valsartan would significantly improve GLS and GCS compared with valsartan alone.
Methods and Results:
PARAMOUNT (Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Trial) was a phase II, randomized, parallel-group, double-blind multicenter trial in 301 patients with New York Heart Association functional class IIâIII heart failure, a left ventricular ejection fraction of 45%, and an N-terminal pro-B-type natriuretic peptide of â„400 pg/mL. Participants were randomly assigned (1:1) to sacubitril/valsartan titrated to 200 mg twice daily or valsartan titrated to 160 mg twice daily for 36 weeks. We assessed changes in the GLS and the GCS from baseline to 36 weeks, adjusting for baseline value, in patients with sufficient imaging quality for 2-dimensitonal speckle tracking analysis at both timepoints (nâŻ=âŻ60 sacubitril/valsartan, nâŻ=âŻ75 valsartan only). GCS was significantly improved at 36 weeks in the sacubitril/valsartan group when compared with the valsartan group (Î4.42%, 95% confidence interval [CI] 0.67â8.17, PâŻ=âŻ.021), with no significant difference observed in GLS (Î0.25%, 95% CI, â1.19 to 1.70, PâŻ=âŻ.73). Patients with a history of hospitalization for heart failure had a differentially greater improvement in GCS when treated with sacubitril/valsartan.
Conclusions:
In patients with heart failure with preserved ejection fraction, sacubitril/valsartan improved GCS but not GLS when compared with valsartan during a 36-week period
Relationship between bone turnover and left ventricular function in primary hyperparathyroidism: The EPATH trial
Observational studies suggested a link between bone disease and left ventricular (LV) dysfunction
that may be pronounced in hyperparathyroid conditions. We therefore aimed to test
the hypothesis that circulating markers of bone turnover correlate with LV function in a
cohort of patients with primary hyperparathyroidism (pHPT). Cross-sectional data of 155
subjects with pHPT were analyzed who participated in the \uaaEplerenone in Primary Hyperparathyroidism
\uba (EPATH) Trial. Multivariate linear regression analyses with LV ejection fraction
(LVEF, systolic function) or peak early transmitral filling velocity (e', diastolic function)
as dependent variables and N-terminal propeptide of procollagen type 1 (P1NP), osteocalcin
(OC), bone-specific alkaline phosphatase (BALP), or beta-crosslaps (CTX) as the
respective independent variable were performed. Analyses were additionally adjusted for
plasma parathyroid hormone, plasma calcium, age, sex, HbA1c, body mass index, mean
24-hours systolic blood pressure, smoking status, estimated glomerular filtration rate, antihypertensive
treatment, osteoporosis treatment, 25-hydroxy vitamin D and N-terminal probrain
B-type natriuretic peptide. Independent relationships were observed between P1NP
and LVEF (adjusted \u3b2-coefficient = 0.201, P = 0.035) and e' (\u3b2 = 0.188, P = 0.042), respectively.
OC (\u3b2 = 0.192, P = 0.039) and BALP (\u3b2 = 0.198, P = 0.030) were each independently
related with e'. CTX showed no correlations with LVEF or e'. In conclusion, high bone formation
markers were independently and paradoxically related with better LV diastolic and,
partly, better systolic function, in the setting of pHPT. Potentially cardio-protective properties of stimulated bone formation in the context of hyperparathyroidism should be explored in
future studies
Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial
<p>Abstract</p> <p>Background</p> <p>Increasing evidence suggests the bidirectional interplay between parathyroid hormone and aldosterone as an important mechanism behind the increased risk of cardiovascular damage and bone disease observed in primary hyperparathyroidism. Our primary object is to assess the efficacy of the mineralocorticoid receptor-blocker eplerenone to reduce parathyroid hormone secretion in patients with parathyroid hormone excess.</p> <p>Methods/design</p> <p>Overall, 110 adult male and female patients with primary hyperparathyroidism will be randomly assigned to eplerenone (25 mg once daily for 4 weeks and 4 weeks with 50 mg once daily after dose titration] or placebo, over eight weeks. Each participant will undergo detailed clinical assessment, including anthropometric evaluation, 24-h ambulatory arterial blood pressure monitoring, echocardiography, kidney function and detailed laboratory determination of biomarkers of bone metabolism and cardiovascular disease.</p> <p>The study comprises the following exploratory endpoints: mean change from baseline to week eight in (1) parathyroid hormone(1â84) as the primary endpoint and (2) 24-h systolic and diastolic ambulatory blood pressure levels, NT-pro-BNP, biomarkers of bone metabolism, 24-h urinary protein/albumin excretion and echocardiographic parameters reflecting systolic and diastolic function as well as cardiac dimensions, as secondary endpoints.</p> <p>Discussion</p> <p>In view of the reciprocal interaction between aldosterone and parathyroid hormone and the potentially ensuing target organ damage, the EPATH trial is designed to determine whether eplerenone, compared to placebo, will effectively impact on parathyroid hormone secretion and improve cardiovascular, renal and bone health in patients with primary hyperparathyroidism.</p> <p>Trial registration</p> <p>ISRCTN33941607</p
Case Report: Assessing the Position of Pacemaker Leads via Transthoracic Echocardiography: Additional Value of the Subcostal En Face View
There is an association between presence of cardiac implantable electronic devices (CIED) and development of tricuspid regurgitation (TR). Mechanisms proposed to explain CIED-induced TR can be classified as implantation-related, lead-related, and pacing-related. Lead-related TR results from the direct interaction of the lead with the tricuspid valve (TV). The localization of the lead at the TV level directly influences the probability of subsequent development of significant TR. A transthoracic subcostal en face view of the TV can be acquired in most patients through a 90 degrees rotation from the subcostal 4-chamber view with clear anatomic delineation of the TV and the commissures including lead position. This case-series presents three examples where the transthoracic en face view could add incremental information on the position of the pacemaker leads and on the mechanism of TR.
Conclusion: When performing transthoracic echocardiography in patients with trans-tricuspid CIED lead(s), an en face view of the TV with exact reporting of the position of the lead(s) should be included